IQVIA Stock Surges 1.20 as $240M Volume Ranks 462nd Amid AI Push and Pharma Alliances

On October 9, 2025, , , ranking 462nd in market activity for the day. The stock's performance was influenced by a strategic shift in its data analytics division, where the company announced expanded partnerships with three major pharmaceutical firms to enhance real-world evidence (RWE) solutions. , signaling sustained demand for IQVIA’s clinical trial optimization services. Analysts noted the developments as a positive catalyst, given the sector’s focus on cost efficiency amid regulatory tightening in drug approval processes.

Market participants observed that IQVIA’s recent earnings call highlighted a 7% year-over-year increase in contract values for its pharma consulting arm, . , targeting a 2026 rollout. While the investment carries short-term margin pressures, the board emphasized long-term revenue diversification benefits. These updates were cited as key factors underpinning the stock’s intra-day momentum, .

To set up this back-test rigorously, I need to pin down a few details that weren’t specified: 1. Market universe—Do we restrict to U.S. listed equities (NYSE + NASDAQ), or another market? 2. Re-balancing mechanics—Each trading day we rank all eligible stocks by that day’s dollar trading volume and buy the top 500 at the next day’s open (holding 1 day), correct? 3. Trading assumptions—Slippage/transaction costs: can we ignore them (default) or would you like to include a fixed bps cost per trade? 4. Benchmark for comparison (e.g., SPY, equal-weight S&P 500, or none)? Once I have these points, I can fetch the required data and run the back-test from 2022-01-01 through today.